Please upgrade your browser.
Researchers also found those with Lynch syndrome faced a moderately increased risk of developing breast and pancreatic cancers. The finding could lead to earlier detection of a wide range of cancers in sufferers.
A 53-year-old woman presented to our hospital with a non-metastatic 4Â cm renal mass in the right kidney. The patient rejected treatment, but consented to follow-up observation of her condition. The patient underwent a series of computed tomography scans to monitor the progression of the disease.
Studies have shown that patients who are engaged in their care report a better quality of life and are more involved in treatment decisions with their health care team.
"The results demonstrate a novel immunomodulatory effect of entinostat and provide a rationale for the clinical testing of entinostat to enhance cancer immunotherapy," said Roberto Pili, MD, professor of oncology, chief, genitourinary section and co-leader, genitourinary program, department of medicine, Roswell Park Cancer Institute.
This study was performed to investigate whether epigallocatechin-3-gallate (EGCG), the major constituent of green tea, interacted with sunitinib.
We report an 18-year-old male patient with metastatic Xp11 translocation RCC who was responsive to sorafenib treatment.
Chronic kidney disease, even on the milder end of the spectrum, is an independent risk factor for urinary cancers and may therefore be useful for targeting screening, the results of a large observational study suggest.
Bill Bro highlights FDA approval of a new drug to treat a certain type of kidney cancer and brings to light a controversial survey that suggests doctors aren't always forthright in dealing with patients.
Doctors report that theyre not always completely honest with patients, especially when it comes to disclosing a medical mistake, or discussing a difficult prognosis, according to a new survey.
A recent study led by scientists at Dana-Farber Cancer Institute found an slightly increased risk of fatal side effects in certain patients treated with VEGF-tyrosine kinase inhibitors. Dr. Toni Choueiri, who led the study, explains what physicians need to know about their patients' medical histories, and how they can help educate patients about the benefits and potential risks of these therapies.
|NeonCRM by Neon One|